Phase I study of KA2507, a selective HDAC6 inhibitor, in patients with relapsed or refractory solid tumors

Phase I study of KA2507, a selective HDAC6 inhibitor, in patients with relapsed or refractory solid tumors. Tsimberidou A.M., Beer P., Bendall J., Dow J., King J., McElwaine-Johnn H. and Wistuba I.I. Abstract CT151. American Association for Cancer Research Virtual Annual Meeting I; April 27-28 2020.

Karus Therapeutics Announces New Data from Phase I Cancer Trial at AACR

Oxfordshire, UK, 27 April 2020 – Karus Therapeutics Ltd (‘Karus’), a clinical-stage biopharmaceutical company developing precision medicines for cancer, announces that new data will be presented from its KA2507 Phase I study at the American Association for Cancer Research (AACR) Annual Meeting 2020. The Phase I clinical trial, conducted at The University of Texas MD […]